Literature DB >> 21952274

Commentary: bevacizumab and erlotinib with chemoradiation for head and neck cancer.

Barbara Burtness1.   

Abstract

Entities:  

Mesh：

Year:  2011        PMID： 21952274     DOI： 10.1097/PPO.0b013e3182326944

Source DB:  PubMed          Journal:  Cancer J        ISSN： 1528-9117            Impact factor:   3.360


× No keyword cloud information.
  2 in total

Review 1.  Application of molecular targeted therapies in the treatment of head and neck squamous cell carcinoma.

Authors:  Paulina Kozakiewicz; Ludmiła Grzybowska-Szatkowska
Journal:  Oncol Lett       Date:  2018-03-20       Impact factor: 2.967

Review 2.  Progresses and Perspectives of Anti-PD-1/PD-L1 Antibody Therapy in Head and Neck Cancers.

Authors:  Bo Yang; Tingjun Liu; Yang Qu; Hangbo Liu; Song Guo Zheng; Bin Cheng; Jianbo Sun
Journal:  Front Oncol       Date:  2018-11-28       Impact factor: 6.244
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.